201 related articles for article (PubMed ID: 21414113)
1. Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic.
Iihara H; Ishihara M; Matsuura K; Kurahashi S; Takahashi T; Kawaguchi Y; Yoshida K; Itoh Y
J Eval Clin Pract; 2012 Aug; 18(4):753-60. PubMed ID: 21414113
[TBL] [Abstract][Full Text] [Related]
2. [Provision of information by pharmacists regarding the effective timing of co-administration of first-generation serotonin receptor antagonists and dexamethasone for chemotherapy-induced nausea and vomiting in patients receiving Doxorubicin and cyclophosphamide chemotherapy for breast cancer].
Nomura H; Kawakami H; Shimizu H; Imi K; Ito H; Isaka H; Shinohara T; Nagai S; Imoto S
Gan To Kagaku Ryoho; 2012 Jan; 39(1):75-9. PubMed ID: 22241355
[TBL] [Abstract][Full Text] [Related]
3. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
4. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
5. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
6. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States.
Craver C; Gayle J; Balu S; Buchner D
J Med Econ; 2011; 14(1):87-98. PubMed ID: 21241160
[TBL] [Abstract][Full Text] [Related]
8. A pilot study to assess the pharmacy impact of implementing a chemotherapy-induced nausea or vomiting collaborative disease therapy management in the outpatient oncology clinics.
Jackson K; Letton C; Maldonado A; Bodiford A; Sion A; Hartwell R; Graham A; Bondarenka C; Uber L
J Oncol Pharm Pract; 2019 Jun; 25(4):847-854. PubMed ID: 29587608
[TBL] [Abstract][Full Text] [Related]
9. Evolving roles of oncology pharmacists in Singapore: a survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre.
Chan A; Shih V; Chew L
J Oncol Pharm Pract; 2008 Mar; 14(1):23-9. PubMed ID: 18337437
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the efforts of pharmaceutical care services before medical examination at an outpatient cancer chemotherapy clinic].
Yoshimi C; Yamada M; Fujii H; Nishigaki M; Iihara H; Kitaichi K; Takahashi M; Kurahashi S; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2013 Mar; 40(3):349-54. PubMed ID: 23507597
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
12. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.
O'Brien BJ; Rusthoven J; Rocchi A; Latreille J; Fine S; Vandenberg T; Laberge F
CMAJ; 1993 Aug; 149(3):296-302. PubMed ID: 8339175
[TBL] [Abstract][Full Text] [Related]
13. Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer.
Miller PJ; Balu S; Buchner D; Walker MS; Stepanski EJ; Schwartzberg LS
J Med Econ; 2013 Oct; 16(10):1179-89. PubMed ID: 23919632
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Dix S; Cord M; Howard S; Coon J; Belt R; Geller R
Bone Marrow Transplant; 1999 Sep; 24(5):561-6. PubMed ID: 10482943
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:
Italian Group For Antiemetic Research
J Clin Oncol; 2004 Feb; 22(4):725-9. PubMed ID: 14966097
[TBL] [Abstract][Full Text] [Related]
17. Delayed chemotherapy-induced nausea in women treated for breast cancer.
Dibble SL; Isreal J; Nussey B; Casey K; Luce J
Oncol Nurs Forum; 2003; 30(2):E40-7. PubMed ID: 12692669
[TBL] [Abstract][Full Text] [Related]
18. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy.
Tina Shih YC; Xu Y; Elting LS
Cancer; 2007 Aug; 110(3):678-85. PubMed ID: 17567835
[TBL] [Abstract][Full Text] [Related]
19. Pharmacist management of antiemetic therapy under protocol in an oncology clinic.
Martin JK; Norwood MB
Am J Hosp Pharm; 1988 Jun; 45(6):1322-8. PubMed ID: 3414699
[TBL] [Abstract][Full Text] [Related]
20. [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1891-903. PubMed ID: 1387775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
